“Background: The use of rapid diagnostic tests (RDTs) for


“Background: The use of rapid diagnostic tests (RDTs) for Plasmodium falciparum malaria

is being suggested to improve diagnostic efficiency in peripheral health care settings in Africa. Such improved diagnostics are critical to minimize overuse and thereby delay development of resistance to artemisinin-based combination therapies (ACTs). Our objective was to study the influence of RDT-aided malaria diagnosis on drug prescriptions, health outcomes, and costs in primary health care settings.

Methods and Findings: We conducted a cross-over SC75741 validation clinical trial in four primary health care units in Zanzibar. Patients of all ages with reported fever in the previous 48 hours were eligible and allocated alternate weeks to RDT-aided malaria diagnosis or symptom-based clinical diagnosis (CD) alone. Follow-up was 14 days. ACT was to be prescribed to patients diagnosed with malaria in both groups. Statistical analyses with multilevel modelling were performed. A Ulixertinib chemical structure total of 1,887 patients were enrolled February through August 2005. RDT was associated with lower prescription rates of antimalarial treatment than CD alone, 361/1005 (36%) compared with 752/882 (85%) (odds ratio [OR] 0.04, 95% confidence interval [CI] 0.03-0.05, p < 0.001). Prescriptions of antibiotics were higher after RDT than CD alone, i.e.,

372/1005 (37%) and 235/882 (27%) (OR 1.8, 95% CI 1.5-2.2, p < 0.001), respectively. Reattendance

due to perceived unsuccessful clinical cure was lower after RDT 25/1005 (2.5%), than CD alone 43/882 (4.9%) (OR 0.5, 95% CI 0.3-0.9, p = 0.005). Total average cost per patient was similar: USD 2.47 and 2.37 after RDT and CD alone, respectively.

Conclusions: RDTs resulted in improved adequate treatment and health outcomes without INCB28060 solubility dmso increased cost per patient. RDTs may represent a tool for improved management of patients with fever in peripheral health care settings.

Trial Registration: Clinicaltrials. gov NCT00549003″
“A monolithic, epitaxially-integrated, vertically-aligned, multi-band photodetector architecture has been demonstrated via the successful growth and fabrication of metamorphic back-to-back n-i-p/p-i-n In(0.61)Ga(0.39)P/In(0.14)Ga(0.86)As visible/near-IR dual-detector devices. The back-to-back diode design enables simultaneous and independent operation of detectors in both bands with low optical cross talk (< – 10 dB outside the 690-720 nm range) and complete electrical isolation between the sub-detectors. The high electronic quality of the resultant metamorphic materials was confirmed via deep level transient spectroscopy, which revealed total trap concentrations of 5 x 10(12) cm(-3) for the In(0.14)Ga(0.86)As and 2 x 10(14) cm(-3) for the In(0.61)Ga(0.

Comments are closed.